Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Gastroesophageal-junction Cancer
Clinical trial register · United States · industry-sponsored

Gastroesophageal-junction Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 8 New York 7 Florida 6 Texas 4 Georgia 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Gastroesophageal-junction Cancer trials in the USA

12 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
NCT07780968Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer
Jazz Pharmaceuticals
Observational
300
California, Texas
2026-11-30
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Maryland, Nevada, New Jersey, New York
2026-05-14
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
California, Rhode Island, Texas
2025-04-29
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
Shanghai Henlius Biotech
Phase 3
550
California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada
2024-11-22
Active, closed
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.
Phase 1
165
California, Massachusetts, Tennessee, Texas
2023-09-14
Active, closed
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 1/2
136
Georgia, Indiana, New York, Tennessee
2021-09-28
Active, closed
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
150
Arizona, Connecticut, Florida, Georgia, Kansas, Missouri, New York, North Carolina
2020-05-28
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Merus B.V.
Phase 1/2
560
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, New York
2018-05-02
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/gastroesophageal-junction-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Gastroesophageal-junction Cancer.

How many Gastroesophageal-junction Cancer trials are recruiting in the US?

6 of the 12 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastroesophageal-junction Cancer), 12 studies
PhaseStudiesRecruitingShare
Phase 1/24133.3%
Phase 33225%
Phase 12116.7%
Observational108.3%
Phase 2118.3%
Phase 2/3118.3%

Most active sponsors

Lead sponsors with the most studies (Gastroesophageal-junction Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca41
Daiichi Sankyo11
Iksuda Therapeutics Ltd.11
Jazz Pharmaceuticals10
Legend Biotech USA Inc10
Merus B.V.11
Pfizer11
Shanghai Henlius Biotech11
Transcenta Therapeutics (Hangzhou) Co., Ltd.10

Top states

Top states (Gastroesophageal-junction Cancer), by number of studies with a site there
StateStudies
California8
New York7
Florida6
Georgia4
Texas4
Colorado3
Illinois3
Massachusetts3
Michigan3
Missouri3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.